Protocol Ledger

NCT05407636 · Phase III · ACTIVE NOT RECRUITING

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Interventional Phase III clinical trial protocol NCT05407636 sponsored by AbbVie in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-13 Enrollment: 735 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05407636
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)735 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05407636
Protocol FieldVerified Registry Value
NCT IdentifierNCT05407636
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment735 participants (ACTUAL)
Registered Start Date2022-01-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI